Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: J Med Chem. 2018 Dec 5;61(24):11341–11348. doi: 10.1021/acs.jmedchem.8b01580

Figure 3.

Figure 3.

The antibacterial activities of compound 6t in vivo. (A) The timeline to evaluate the antibacterial activities of 6t in in a mouse peritonitis model at 12 h after MRSA infection. PTM and vancomycin (50 mg/kg) was used as the positive controls and physiological saline was used as the negative control. (B) The CFUs of S. aureus in the blood of infected mice with different treatments. (C) The CFUs of S. aureus in the kidney of infected mice with different treatments. Each point represents data from a single mouse. Mean values are presented, n = 5. Error bars indicate ± SEM. The CFUs were analyzed using unpaired two-tailed Student’s t-test. A probability value of p < 0.05 (∗) or p < 0.01 (∗∗) was considered significant, while p > 0.05 (ns) was considered insignificant. (D) The timeline to evaluate the antibacterial activities of 6t in in a mouse peritonitis model for 7 days after MRSA infection, in comparison to PTM (n = 5 mice per group). Vancomycin was used as the positive control and physiological saline was used as the negative control. The infected mice were inspected twice every day and their survival and body weights were tracked for 7 days. (E) The NO. of survived mice after treatment. (F) The weights of the survived mice in the period of 7 days.